checkmate 274: adjuvant nivolumab versus placebo for urothelial carcinoma
Published 3 years ago • 433 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
2:06
checkmate 274: nivolumab versus placebo in high-risk urothelial cancer
-
2:19
checkmate 274: biomarkers linked to disease-free survival with adjuvant nivolumab
-
2:13
adjuvant nivolumab as soc for high-risk muscle-invasive urothelial carcinoma after radical resection
-
12:12
checkmate 274 adjuvant nivolumab in urothelial cancer | an oncologist's take
-
4:22
checkmate 274 & ev-301: highlights in uc from asco gu
-
2:22
adjuvant nivolumab in patents with high-risk resected melanoma
-
2:53
matthew galsky, md, elaborates on outcomes from the checkmate 274 trial
-
2:36
matthew galsky, md, on the checkmate-274 study in high risk, muscle-invasive urothelial carcinoma
-
9:10
adjuvant nivolumab in resected oesophageal or goj cancer following chemo
-
4:14
adjuvant nivolumab in patients with resected esophageal or gej cancer (checkmate 577)
-
5:44
4-year results from checkmate 238: adjuvant nivo vs ipi in resected stage iii/iv melanoma
-
2:06
checkmate 901: nivolumab with gemcitabine-cisplatin in urothelial carcinoma
-
2:09
checkmate 032: nivolumab/ipilimumab for urothelial carcinoma
-
3:12
nivolumab for perioperative esophageal and gastroesophageal cancer: checkmate 577
-
3:08
adjuvant nivolumab after chemo-radiation for localized muscle-invasive bladder cancer
-
9:24
key updates in bladder cancer from asco gu 2021
-
2:56
encouraging phase 3 checkmate 238 data: adjuvant nivolumab in resected stage iii/iv melanoma
-
7:39
adjuvant nivolumab versus ipilimumab for resected stage iii/iv melanoma
-
2:31
key immunotherapy combinations for urothelial cancer